| Bioactivity | EG1, a specific Pax2 inhibitor, directly binds the paired domain of Pax2 (Kd=1.35-1.5 μM) and inhibits Pax2-DNA interactions. EG1 can inhibit embryonic kidney development, a process directly dependent on Pax2 activity[1]. | ||||||||||||
| Invitro | EG1 (0-12.5 μM; 48 hours) decreases viability in Pax2 positive renal cancer cell lines[1].EG1 (0-500 μM) is capable of inhibiting Pax2 mediated expression of EGFP without significant effects on Pax2 protein levels[1]. Cell Viability Assay[1] Cell Line: | ||||||||||||
| Name | EG1 | ||||||||||||
| CAS | 693241-54-2 | ||||||||||||
| Formula | C22H18N2O5 | ||||||||||||
| Molar Mass | 390.39 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Grimley E, et al. Inhibition of Pax2 Transcription Activation with a Small Molecule that Targets the DNA Binding Domain. ACS Chem Biol. 2017;12(3):724-734. |